LISINOPRIL TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Kaufe es jetzt

Fachinformation Fachinformation (SPC)
19-04-2011

Wirkstoff:

LISINOPRIL

Verfügbar ab:

MELIAPHARM INC

ATC-Code:

C09AA03

INN (Internationale Bezeichnung):

LISINOPRIL

Dosierung:

5MG

Darreichungsform:

TABLET

Zusammensetzung:

LISINOPRIL 5MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/500

Verschreibungstyp:

Prescription

Therapiebereich:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0121550003; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2014-06-25

Fachinformation

                                PRODUCT MONOGRAPH
PR
LISINOPRIL
(lisinopril tablets, USP)
Tablets 5, 10 and 20 mg
Angiotensin Converting Enzyme Inhibitor
MELIAPHARM INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
April 19, 2011
Submission Control No: 145666
2
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
LISINOPRIL
(lisinopril tablets, USP)
Tablets 5, 10 and 20 mg
THERAPEUTIC CLASSIFICATION
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an ACE inhibitor which is used in the treatment of
hypertension, congestive heart
failure and following myocardial infarction in hemodynamically stable
patients.
Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum K
+
. In patients treated with lisinopril
and a thiazide
diuretic there was essentially no change in serum potassium (see
PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of lisinopril has not
been associated with a rapid
increase in blood pressure. In most patients studied, after oral
administration of an individual
dose of lisinopril, the onset of antihypertensive activity is seen at
one hour with peak reduction
of blood 
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Dokumente in anderen Sprachen

Fachinformation Fachinformation Französisch 19-04-2011

Suchen Sie nach Benachrichtigungen zu diesem Produkt

Dokumentverlauf anzeigen